45
Participants
Start Date
October 6, 2020
Primary Completion Date
April 15, 2024
Study Completion Date
April 15, 2024
CG-806
CG-806 will be given orally in ascending doses starting at 450 mg PO BID until the maximum tolerated dose or candidate recommended Phase 2 dose is reached.
Memorial Sloan Kettering Cancer Center, New York
Roswell Park Comprehensive Cancer Center, Buffalo
University of Miami, Miami
University Hospital of Cleveland, Cleveland
Northwestern University, Chicago
Ochsner Healthcare, New Orleans
University of Texas MD Anderson Cancer Center, Houston
University of Southern California, Los Angeles
City of Hope National Medical Center, Duarte
Atlantic Hematological Oncology Center, Morristown
Lead Sponsor
Aptose Biosciences Inc.
INDUSTRY